Are the PCSK9 inhibitors the panacea of atherosclerosis treatment?

References

• Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366:1108–1118. ​​
   PubMed Web of Science ®Google Scholar
• Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol. 2012;60:1888–1898.
   PubMed Web of Science ®Google Scholar
• Everett BM, Smith RJ, Hiatt WR. Reducing LDL with PCSK9 inhibitors — the clinical benefit of lipid drugs. N Engl J Med. 2015;373:1588–1591.
   PubMed Web of Science ®Google Scholar
• Takagi H, Umemoto T, for the ALICE Group. Limit to benefits of large reductions in low-density lipoprotein cholesterol levels: use of fractional polynomials to assess the effect of low-density lipoprotein cholesterol level reduction in metaregression of large statin randomized trials. JAMA Intern Med. 2013;173:1028–1029.
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 suppl 2):S1–S45.
   PubMed Web of Science ®Google Scholar
• Fazio S, MacRae F, Linton MF. Debate: “How low should LDL cholesterol be lowered?” Viewpoint: “It doesn’t need to be very low”. Curr Control Trials Cardiovasc Med. 2001;2:8–11.
   PubMedGoogle Scholar
• Sniderman A, Thanassoulis G, Couture P, et al. Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists’ Collaboration meta-analysis for low-density lipoprotein lowering. J Clin Lipidol. 2012;6:303–309.
   PubMed Web of Science ®Google Scholar
• Everett BM, Mora S, Glynn RJ, et al. Safety profile of subjects treated to very low low-density lipoprotein cholesterol levels (<30 mg/dl) with rosuvastatin 20 mg daily (from JUPITER). Am J Cardiol. 2014;114:1682–1689.
   PubMed Web of Science ®Google Scholar
• Robinson JG, Rosenson RS, Farnier M, et al. Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials. Jacc. 2017;69:471–482.
   Web of Science ®Google Scholar
• Cannon CJ, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Wiviott SD, Blazing MA, et al. Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a prespecified analysis of the IMPROVE-IT trial. JAMA Cardiol. 2017 Mar;14. [Epub ahead of print]. DOI:10.1001/jamacardio.2017.0083
   Web of Science ®Google Scholar
• Sabatine M, Giugliano RP, Keech A, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. Nejm. 2017;376:1713–1722. DOI:10.1056/NEJMoa1615664
   PubMed Web of Science ®Google Scholar
• Stein EA. What role will PCSK9 inhibitors play in hyperlipidemia management? Curr Opin Endocrinol Diabetes Obes. 2016 Apr;23(2):97–105.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Stein EA, Dufour R, et al.; for the RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:331–340.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:341–350.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Stroes E, Dent-Acosta RE, et al. GAUSS-3 investigators; efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315(15):1580–1590.
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Kjekshus J, Berg K, et al. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Wiviott SD, et al., on behalf of the OSLER Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. New Engl J Med. 2015;372:1500–1509.
   PubMed Web of Science ®Google Scholar
• Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489–1499.
   PubMed Web of Science ®Google Scholar
• Amgen is getting whacked after disappointing study results for its $14,000 heart drug (AMGN) [cited 2017 Mar 30]. Available from: http://markets.businessinsider.com/news/stocks/r-amgen-cholesterol-drug-cuts-heart-attack-stroke-risk-more-than-20-percent-study-2017-3-1001845997
   Google Scholar
• Sabatine MS, Giugliano RP, Keech A, et al. Rationale and design of the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial. Am Heart J. 2016;173:94–101.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016;316:2373–2384.
   PubMed Web of Science ®Google Scholar
• Ray KK, Ginsberg HN, Davidson MH, et al. Reductions in atherogenic lipids and major cardiovascular events: a pooled analysis of 10 ODYSSEY trials comparing alirocumab to control. Circulation. 2016;134:1931–1943.
   PubMed Web of Science ®Google Scholar
• [cited 2017 Mar 30]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125522s000lbl.pdf
   Google Scholar
• [cited 2017 Mar 30]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125559Orig1s000lbledt.pdf
   Google Scholar
• Ridker PM, Revkin J, Amarenco P, et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. Nejm. 2017 Mar 17. DOI:10.1056/NEJMoa1701488.
   Web of Science ®Google Scholar
• Ference BA, Robinson JG, Brook RD, et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med. 2016;375:2144–2153.
   PubMed Web of Science ®Google Scholar
• Schmidt AF, Swerdlow DI, Holmes MV, et al. PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol. 2017;5:97–105.
   PubMed Web of Science ®Google Scholar
• Stein EA, Raal FJ. Targeting LDL: is lower better and is it safe? Best Pract Res Clin Endocrinol Metab. 2014;28:309–324.
   PubMed Web of Science ®Google Scholar
• Stein EA, Turner T, Plunkett N, et al. Friedewald formula significantly underestimates LDL cholesterol compared to preparative ultracentrifugation below 70 mg/dL leading to overestimation of the LDL cholesterol reduction for new drugs in development. Jacc. 2014;63(12):A1457. DOI:10.1016/S0735-1097(14)61457-1
   Google Scholar
• EMDAC: Alirocumab Briefing Document June. 2015. [cited 2017 Feb 28]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM449865.pdf
   Google Scholar